mardi 25 juin 2019

Onco Actu du 25 juin 2019


3.1.1 PRÉVENTION - TABAC - E-CIGS



The debate over e-cigarettes demands stronger evidence of their value [Nature]










4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Interim Scan during Prostate Cancer Therapy Helps Guide Treatment [SNMMI]











Nuclear Medicine PSMA-Targeted Study Offers New Options for Cancer Theranostics Worldwide [SNMMI]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



As Million European Genomes Initiative Advances, Alliance Promotes New Personalized Medicine Project [Genome Web]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



‘I can change it for others’: the woman who exposed Irish smear tests scandal [The Guardian]











4.9 DÉP., DIAG. & PRONO. - SEIN



Infrared imaging technology being developed to better detect breast cancer [Rochester Institute of Technology]











The popularity of 3D mammograms is taking off, but not in every part of the US, study says [CNN]











More women in U.S. receive 3-D mammography but disparities remain [Yale University]










5. TRAITEMENTS



Which Neoadjuvant Treatment Strategy for High-Risk Resectable Melanoma? [ESMO]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Hope for aggressive breast cancers as diabetes drug creates new potential avenue for treatment [Breast Cancer Now]











5.10 TRAITEMENTS - ESSAIS



FDA lifts hold on AbbVie, Roche's Venclexta in myeloma after drugmakers pledge risk remedies [Fierce Pharma]











FDA lifts hold on AbbVie multiple myeloma study [Biopharma Dive]











AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality [AbbVie]











AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud [EndPoints]










5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



How inhibiting both HDAC and PD-1 could improve immuno-oncology treatments [Fierce Biotech]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Bristol-Myers Squibb’s Opdivo misses its shot at earlier use in liver cancer [Fierce Pharma]










Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma [BMS]











Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market [EndPoints]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Wearable Technology to Personalize Lu-177-DOTATATE Therapy for NETs [SNMMI]











5.2 PHARMA



GSK wins speedy FDA Zejula review in ovarian cancer niche [Fierce Pharma]











U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review [GSK]











6.1 OBSERVATION



Survivors of Childhood Brain Tumors Experience Lasting Cognitive and Socioeconomic Burdens [Wiley]











6.7 DMP, BIG DATA & APPLIS



PatientsLikeMe, forced by U.S. to ditch Chinese investor, sold to UnitedHealth Group [STAT]